Clinical Guidelines May Reduce Unnecessary Prostate Cancer Imaging

Published Online: Monday, September 16, 2013
Follow Pharmacy_Times:
Providing clinicians with prostate cancer imaging information and guidelines may help to reduce the amount of inappropriate imaging, suggests a recent study conducted in Sweden.

To reduce national rates of inappropriate prostate cancer imaging, the national Prostate Cancer Register of Sweden has supplied urologists with imaging guidelines and utilization data since 2000. The study, published online on July 13, 2013, in the Journal of the National Cancer Institute, analyzed the effects of this campaign on prostate cancer imaging rates in 99,879 men diagnosed with prostate cancer from 1998 to 2009. Cancers were categorized as low, intermediate, or high risk, and imaging rates were evaluated over time and regionally.

A total of 36% of participants underwent imaging within 6 months of their prostate cancer diagnosis. Among men with low-risk prostate cancer, imaging rates decreased from 45% before the campaign to just 3% in 2009. Imaging rates for high-risk cancer patients decreased as well, from 63% to 47%. Although the results varied by region, each area experienced statistically significant drops in prostate cancer imaging.

Inappropriate use of imaging in low-risk prostate cancer patients is a problem recognized by organizations such as the American Society of Clinical Oncology. The authors suggest that a US campaign to promote imaging guidelines may also be effective in reducing prostate cancer imaging.

Related Articles
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
A vaccine therapy that stimulates the body’s own immune defenses is safe to give to prostate cancer patients early in the disease’s progression, a recent study found.
Researchers have developed a personalized genetic test that can accurately predict the risk for recurrence in prostate cancer patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$